InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Are generic manufacturer patents driving up drug prices?

Peter Leung, Hong Kong


A study from the University of Melbourne shows that Australia’s most expensive drugs are attached to patents not held by the innovator company

The paper, entitled "Patents Associated with High-Cost Drugs in Australia", examined 15 of the costliest drugs in Australia over the past 20 years and the patents associated with them, and found that each had an average of 49 associated patents. There...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain FREE access to up to five free articles when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

@TTABlog @TrademarkBlog 100% is never enough!

Oct 23 2017 12:41 ·  reply ·  retweet ·  favourite
ManagingIP profile

Important statement from @ipfederation https://t.co/xn678q06BY

Oct 23 2017 12:27 ·  reply ·  retweet ·  favourite
ManagingIP profile

RT @MannySchecter: Inventors and entrepreneurs in need of free #patent info/advice should see here, courtesy of the USPTO: https://t.co/TPb

Oct 23 2017 12:26 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


null null null

null null null

October 2017

Courts grapple with scope of patent protection

The Supreme Court’s decision in Actavis v Eli Lilly introduced a doctrine of equivalents and arguably also established a doctrine of prosecution history estoppel in the UK. We look at the law across Europe, and the impact the decision might have. Kingsley Egbuonu, Michael Loney and James Nurton set the scene



Most read articles

Supplements